NVS : Analysis & Opinions

  1. Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook

    March 25, 2014
    Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
  2. Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook

    December 3, 2013
    Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
  3. Array - Loxo Collaborate - Analyst Blog

    July 11, 2013
    Array BioPharma and Loxo Oncology announced a license and collaboration agreement.
  4. GW Pharma's Sativex Launched in Italy - Analyst Blog

    July 11, 2013
    GW Pharma announced that Sativex has been launched in Italy.
  5. Array Begins Phase III Study on MEK162 - Analyst Blog

    July 9, 2013
    Array initiated a phase III study on MEK162 in patients suffering from LGSOC.
  6. Positive Data for Novartis' Candidate - Analyst Blog

    July 9, 2013
    Novartis recently announced encouraging top-line data from a phase III study, FIXTURE, on psoriasis candidate, secukinumab ...
  7. Good News for Omeros on OMS302 - Analyst Blog

    July 5, 2013
    The EMA approved the positive opinion rendered by the European Pediatrics Committee related to Omeros' pediatric investigation ...
  8. Label Expansion for Novartis' Lucentis - Analyst Blog

    July 5, 2013
    Novartis recently received positive news when the European Commission approved its ophthalmology drug, Lucentis, for an additional ...
  9. Taking The Contrarian Approach With European Equities

    July 2, 2013
    Investors continue to shun European equities due to the regions debt issues and economic problems. However, that’s a real ...
  10. ViroPharma and Other Biotech Stocks Recommended by Oppenheimer ...

    June 24, 2013
    Oppenheimer has a new team of analysts focused on biotechnology and specialty pharmaceuticals. And, research from the new ...
  11. Novo Nordisk Patent Found Invalid - Analyst Blog

    June 19, 2013
    Novo Nordisk announced that the US Court of Appeals for the Federal Circuit has found the patent on its diabetes drug, Prandin ...
  12. Positive Data on Incyte's Jakafi - Analyst Blog

    June 18, 2013
    Incyte announced positive long-term data from two ongoing studies on Jakafi.
  13. Ariad's Iclusig in GIST Phase II Study - Analyst Blog

    June 18, 2013
    The study will evaluate Iclusig's efficacy and safety in patients who have failed at least one tyrosine kinase inhibitor ...
  14. Questcor Surges on Drug Acquisition - Analyst Blog

    June 12, 2013
    Shares of Questcor received a major boost when the company announced the acquisition of development and commercialization ...
  15. AstraZeneca Pays Up To Patch Up Another Key Area

    June 10, 2013
    In buying Pearl, AstraZeneca is taking some of the risk out of its valuable COPD franchise.
  16. Actavis Challenges Patents - Analyst Blog

    June 10, 2013
    Actavis is looking to launch its generic versions of Diprivan and Safyral.
  17. Top-Performing Dividend Payers in Health Care with the Most Upside ...

    June 8, 2013
    It is not unusual for stocks on a tear to overrun their mean price targets, which is a signal of how far analysts on average ...
  18. Teva Still Too Cheap, But Still Too Uncertain

    May 3, 2013
    Teva's present-day momentum is weak, but the value could appeal to patient long-term investors.
  19. Jacobs' Deal Win in Saudi Arabia - Analyst Blog

    February 13, 2013
    Saudi Aramco Lubricating Oil Refining Co. (Luberef), recently awarded Jacobs Engineering Group Inc. (JEC), a construction ...
  20. A Mixed Quarter for Hologic - Analyst Blog

    February 8, 2013
    Hologic (HOLX) reported net income of $3.1 million or a penny per share in the first quarter of fiscal 2013 compared with ...
  21. Pipeline Progress at Glaxo - Analyst Blog

    February 4, 2013
    Recently, GlaxoSmithKline (GSK) announced the initiation of a phase III study (COMBI-AD) to evaluate its oncology candidate ...
  22. Valeant Closes Natur Acquisition - Analyst Blog

    February 4, 2013
    Valeant Pharmaceuticals International, Inc. (VRX) recently closed the acquisition of Russia-based Natur Produkt International, ...
  23. Generic Launch at Dr. Reddy's - Analyst Blog

    January 28, 2013
    Dr. Reddy's Laboratories (RDY) recently announced the launch of its generic version of Merck & Co's (MRK) Singulair oral ...
  24. Theravance Winds up Public Offering - Analyst Blog

    January 28, 2013
    Theravance, Inc. (THRX) recently announced that it has completed its public offering of $287.5 million convertible subordinated ...
  25. Amgen Misses on EPS, Guides Above - Analyst Blog

    January 24, 2013
    Amgen (AMGN) reported fourth quarter 2012 earnings of $1.39 per share, 4 cents below the Zacks Consensus Estimate. Earnings, ...
  26. Positive CHMP Opinions for Novartis - Analyst Blog

    January 23, 2013
    Novartis' (NVS) global eye care division, Alcon, recently received a positive opinion from the Committee for Medicinal Products ...
  27. PetMed Revs in Line, Margins Up - Analyst Blog

    January 23, 2013
    America's largest pet pharmacy, PetMed Express (PETS) reported earnings of 23 cents per share in the third quarter of fiscal ...
  28. Management Expands at AstraZeneca - Analyst Blog

    January 17, 2013
    AstraZeneca (AZN) recently announced that the company has created seven positions in the senior executive team. At the same ...
  29. Theravance to Offer Notes - Analyst Blog

    January 17, 2013
    Theravance, Inc. (THRX) announced recently that it intends to offer $250 million convertible subordinated notes, due in 2 ...
  30. InterMune to Raise Funds - Analyst Blog

    January 16, 2013
    InterMune Inc. (ITMN) recently announced its intention to raise funds through concurrent underwritten public offerings. InterMune ...
  31. EU Expands J&J Zytiga Label - Analyst Blog

    January 16, 2013
    Johnson & Johnson's (JNJ) Janssen-Cilag International NV recently announced that the European Commission (EC) has granted ...
  32. Upbeat Data on Novartis' Bexsero - Analyst Blog

    January 15, 2013
    As per recent data published in The Lancet, Novartis' (NVS) vaccine candidate, Bexsero (meningococcal group B vaccine [rDNA, ...
  33. Glaxo Seeks Albiglutide Approval - Analyst Blog

    January 15, 2013
    GlaxoSmithKline (GSK) recently announced the submission of a marketing application to the US Food and Drug Administration ...
  34. J&J Drug Supported by FDA Panel - Analyst Blog

    January 14, 2013
    Janssen Research & Development, LLC, a Johnson & Johnson (JNJ) company, recently announced that the FDA's Endocrinologic ...
  35. Lilly to Go Solo with LY2605541 - Analyst Blog

    January 11, 2013
    Eli Lilly and Company (LLY) recently announced that it will be developing diabetes candidate, LY2605541, on its own. The ...
  36. Infinity Provides Pipeline Update - Analyst Blog

    January 11, 2013
    Infinity Pharmaceuticals Inc. (INFI) recently provided an update on its pipeline and issued its guidance for 2013. The company ...
  37. Shire to Buy Lotus Tissue Repair - Analyst Blog

    January 10, 2013
    Shire plc (SHPG) recently announced its intention to acquire privately-held biotech company, Lotus Tissue Repair, Inc.  ...
  38. Glaxo/THRX Seek European Approval - Analyst Blog

    January 10, 2013
    GlaxoSmithKline (GSK) and Theravance, Inc. (THRX) recently announced the submission of a marketing application to the European ...
  39. Sanofi Acquires Rolaids Rights - Analyst Blog

    January 8, 2013
    Sanofi's (SNY) US consumer healthcare division, Chattem, Inc., recently announced that it has acquired worldwide rights of ...
  40. Impax Launches Opana ER Generic - Analyst Blog

    January 7, 2013
    Global Pharmaceuticals, the generic division of Impax Laboratories, Inc. (IPXL), a specialty pharmaceutical company, recently ...
  41. FDA Accepts Merck Combo Therapy NDA - Analyst Blog

    January 7, 2013
    Merck (MRK) recently announced that its resubmitted new drug application (NDA) for its ezetimibe and atorvastatin combination ...
  42. Positive Data on Alkermes Candidate - Analyst Blog

    January 4, 2013
    Alkermes plc (ALKS) recently announced positive results from a phase I study on its new antipsychotic candidate, ALKS 3831. ...
  43. XOMA Provides Update on Gevokizumab - Analyst Blog

    January 2, 2013
    XOMA Corporation (XOMA) recently announced that it intends to include active non-infectious anterior scleritis in the gevokizumab ...
  44. Emergent Inks Deal with VaxInnate - Analyst Blog

    December 31, 2012
    Specialty pharmaceutical company, Emergent BioSolutions (EBS), recently signed a license agreement to gain an exclusive manufacturing ...
  45. UTHR Reiterated at Neutral - Analyst Blog

    December 31, 2012
    We recently reiterated a Neutral recommendation on United Therapeutics (UTHR). While the company reported strong third-quarter ...
  46. Dendreon Sells Manufacturing Unit - Analyst Blog

    December 27, 2012
    Dendreon Corporation (DNDN) recently sold its immunotherapy manufacturing facility (IMF) to Novartis Pharmaceuticals Corporation ...
  47. US Approval for Novartis' Signifor - Analyst Blog

    December 17, 2012
    The US Food and Drug Administration ("FDA") recently approved Novartis' (NVS) Signifor (pasireotide) to treat adults suffering ...
  48. Myriad Teams Up with Sanofi - Analyst Blog

    December 11, 2012
    Myriad RBM, a wholly-owned subsidiary of molecular diagnostic company Myriad Genetics Inc. (MYGN), has recently collaborated ...
  49. PDLI Guides Q4 Royalty Rev to $86M - Analyst Blog

    December 7, 2012
    PDL BioPharma Inc. (PDLI) recently announced that it expects to generate fourth quarter 2012 royalty revenues of $86 million, ...
  50. Data Published on ARIAD Candidate - Analyst Blog

    November 30, 2012
    ARIAD Pharmaceuticals (ARIA) recently announced the publishing of results from a phase I dose-escalation study of ponatinib ...
  51. NVS Discusses Data Readout Plans - Analyst Blog

    November 29, 2012
    Swiss pharmaceutical giant Novartis (NVS) recently announced that it intends to present key data from studies in patients ...
  52. Pipeline Advances at Supernus - Analyst Blog

    November 26, 2012
    Supernus Pharmaceuticals, Inc. (SUPN) recently announced encouraging top-line results from a phase IIb study, which is evaluating ...
  53. Positive Data on XOMA Candidate - Analyst Blog

    November 26, 2012
    XOMA Corporation (XOMA) recently announced encouraging data from a phase III study PATH (Perindopril Amlodipine for the Treatment ...
  54. Fiat Finally Convinces CNH To Seal The Deal

    November 26, 2012
    CNH Global agreed to merge into a new company with Fiat Industrial. Find out what this means for shareholders.
  55. Sanofi's Aubagio Gets Australian Nod - Analyst Blog

    November 23, 2012
    Sanofi (SNY) and its subsidiary Genzyme recently announced that their oral candidate for relapsing forms of multiple sclerosis ...
  56. Alnylam-Tekmira Settle Up - Analyst Blog

    November 19, 2012
    Alnylam Pharmaceuticals, Inc. (ALNY) and Tekmira Pharmaceuticals Corporation recently signed a new licensing agreement and ...
  57. PDLI's EPS In Line, Revenue Misses - Analyst Blog

    November 7, 2012
    PDL BioPharma Inc. (PDLI) posted third-quarter earnings of 32 cents per share, in line with the Zacks Consensus Estimate ...
  58. Positive Data on Sanofi's Aubagio - Analyst Blog

    October 24, 2012
    Sanofi (SNY) and its subsidiary Genzyme recently presented positive data on its oral treatment for relapsing forms of multiple ...
  59. Beat and Raise Quarter for Amgen - Analyst Blog

    October 24, 2012
    Amgen (AMGN) continued its strong performance in 2012 with third quarter earnings coming in at $1.66 per share, 23 cents ...
  60. Generic Launches at Watson Pharma - Analyst Blog

    October 23, 2012
    Watson Pharmaceuticals, Inc. (WPI) recently announced that it has gained US Food and Drug Administration (FDA) approval for ...
  61. FDA Extends Review of Impax' IPX066 - Analyst Blog

    October 16, 2012
    The US Food and Drug Administration (FDA) recently extended the Prescription Drug User Fee Act (PDUFA) date for Impax Laboratories, ...
  62. Mylan in Neutral Lane - Analyst Blog

    October 10, 2012
    We are maintaining our Neutral recommendation on Mylan Inc. (MYL) with a target price of $26.00. The stock carries a Zacks ...
  63. PDLI-AxoGen Complete Financing Deal - Analyst Blog

    October 10, 2012
    PDL BioPharma, Inc. (PDLI) and AxoGen, Inc. (AXGN) recently completed a structured financing transaction. As per the financing ...
  64. ARIAD Seeks Ponatinib Approval - Analyst Blog

    October 2, 2012
    ARIAD Pharmaceuticals, Inc. (ARIA) recently completed the rolling submission of the New Drug Application (NDA) for its oncology ...
  65. Biogen's Hemophilia B Drug Scores - Analyst Blog

    September 27, 2012
    Biogen Idec (BIIB) and partner, Swedish Orphan Biovitrum, recently presented positive phase III top-line results on their ...
  66. Valeant Buys QLT's Visudyne - Analyst Blog

    September 26, 2012
    Valeant Pharmaceuticals International, Inc. (VRX) recently announced that it has acquired QLT Inc.'s (QLTI) Visudyne. To ...
  67. Glaxo Back on a Neutral Path - Analyst Blog

    September 25, 2012
    GlaxoSmithKline plc (GSK) performed disappointingly in the second quarter of 2012, missing the Zacks Consensus Estimate both ...
  68. Dr. Reddy's Launches Generic Amoxil - Analyst Blog

    September 21, 2012
    Dr. Reddy's Laboratories (RDY) recently announced the launch of its generic version of GlaxoSmithKline's (GSK) Amoxil (amoxicillin) ...
  69. CPIX Reports Encouraging Data - Analyst Blog

    September 20, 2012
    Cumberland Pharmaceuticals Inc. (CPIX) recently announced encouraging top-line results from a phase IV study on Caldolor ...
  70. Pfizer-Hisun JV Launched - Analyst Blog

    September 18, 2012
    Pfizer (PFE) and Chinese pharmaceutical company, Zhejiang Hisun Pharmaceuticals, recently announced the launch of their joint ...
  71. Shire Aims to Expand Vyvanse Label - Analyst Blog

    September 17, 2012
    Shire plc (SHPG) recently announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental ...
  72. Apricus, Takeda Ink Marketing Deal - Analyst Blog

    September 14, 2012
    Apricus Biosciences, Inc. (APRI) and Takeda Pharmaceuticals (TKPYY) recently signed an exclusive licensing agreement to market ...
  73. Sanofi MS Drug Gets Approval - Analyst Blog

    September 13, 2012
    Sanofi (SNY) and its subsidiary Genzyme recently announced that their oral candidate for relapsing forms of multiple sclerosis ...
  74. Shire Settles Patent Dispute - Analyst Blog

    September 12, 2012
    Shire LLC, a subsidiary of Shire plc (SHPG) recently announced that it has entered into a settlement agreement with Anchen ...
  75. Dr. Reddy's Launches Generic Toprol - Analyst Blog

    September 12, 2012
    Dr. Reddy's Laboratories (RDY) recently announced the launch of its generic version of AstraZeneca's (AZN) hypertension drug ...
  76. PDLI Guides Q3 Royalty Rev to $85M - Analyst Blog

    September 7, 2012
    PDL BioPharma Inc. (PDLI) recently announced that it expects to generate third quarter 2012 royalty revenues of $85 million, ...
  77. Alnylam Presents Data on ALN-RSV01 - Analyst Blog

    September 6, 2012
    Alnylam Pharmaceuticals, Inc. (ALNY) recently presented complete results from a phase IIb trial on ALN-RSV01 at the European ...
  78. Sanofi's Lemtrada US Filing Update - Analyst Blog

    August 28, 2012
    Sanofi's (SNY) subsidiary, Genzyme, recently announced that the US Food and Drug Administration (FDA) has issued a refuse-to-file ...
  79. Good News for Perrigo Generics - Analyst Blog

    August 13, 2012
    Perrigo Company (PRGO) recently received some good news when the US Food and Drug Administration (FDA) cleared its generic ...
  80. Update on Teva's Laquinimod - Analyst Blog

    August 9, 2012
    Teva Pharmaceutical Industries Ltd. (TEVA) and Active Biotech recently announced that they intend to commence a phase III ...
  81. Alnylam Earns Milestone Payment - Analyst Blog

    August 6, 2012
    Alnylam Pharmaceuticals Inc. (ALNY) recently earned development milestone payment of $3.2 million from GlaxoSmithKline (GSK). ...
  82. PDL BioPharma Beats Zacks Estimates - Analyst Blog

    August 6, 2012
    PDL BioPharma Inc. (PDLI) posted second-quarter earnings of 53 cents per share, above the year-ago figure of 39 cents and ...
  83. Biogen Beats on All Fronts - Analyst Blog

    July 24, 2012
    Biogen Idec (BIIB) reported second quarter earnings per share of $1.82, well above the Zacks Consensus Estimate of $1.56 ...
  84. Dr. Reddy's Launches Generic Lipitor - Analyst Blog

    July 19, 2012
    Yet another generic version of Pfizer's (PFE) cholesterol drug, Lipitor (atorvastatin calcium), entered the market recently ...
  85. GolinHarris Acquires Virgo Health - Analyst Blog

    July 6, 2012
    GolinHarris, a division of Interpublic Group (IPG) intends to acquire Virgo Heath, an independent UK-based Healthcare Communications ...
  86. FDA Nod for Perrigo Generic - Analyst Blog

    June 29, 2012
    Perrigo Co. (PRGO) recently announced that it had received US Food and Drug Administration (FDA) approval for its abbreviated ...
  87. Fallacy Of International ETFs

    June 26, 2012
    The expansion of the ETF industry over the last several years has been well documented; there are now more than 1,400 exchange-traded ...
  88. BMY Presents Data on Sprycel - Analyst Blog

    June 18, 2012
    Recently, Bristol-Myers Squibb Company (BMY) and partner Otsuka Pharmaceutical Europe Ltd. presented six-year follow-up data ...
  89. PDL BioPharma Guides Q2 Royalty Rev to $125M - Analyst Blog

    June 14, 2012
    PDL BioPharma Inc. (PDLI) recently announced that it expects to generate second-quarter 2012 royalty revenues of $125 million, ...
  90. New Lease Agreements for Alexandria - Analyst Blog

    June 8, 2012
    Alexandria Real Estate Equities, Inc. (ARE), a real estate investment trust (REIT), recently entered into long-term agreements ...
  91. Earnings Beat at PDL BioPharma - Analyst Blog

    May 8, 2012
    PDL BioPharma Inc. (PDLI) posted first quarter earnings of 30 cents per share, above the year-ago figure of 25 cents and ...
  92. Eli Lilly Paying Investors To Wait

    May 3, 2012
    The pharmaceutical giant reported decent first quarter results late in April 2012. However, It will likely be some time before ...
  93. QUAD GRAPHICS (QUAD) - Profit Tracks

    May 1, 2012
    QUAD GRAPHICS (QUAD) - Profit Tracks
  94. J&J Sticking Together

    April 23, 2012
    There is turnaround potential at J&J as it regains its former glory. The company has decided that operating a diversified ...
  95. 2011 In Review - Pharmaceuticals

    December 29, 2011
    2011 was a surprisingly healthy year for drug stocks.
  96. Sanofi's Investment Prospects

    December 21, 2011
    Sanofi has emerged as an unheralded value in pharmaceuticals.
  97. If Pipelines Matter, Novartis Should Be Looking Healthy

    November 30, 2011
    When a company like Novartis comes down the road with a healthy pipeline, the Street seems to respond with worries.
  98. Biogen Idec Has Built A Valuable Franchise

    November 1, 2011
    Biogen Idec is a go-to name in MS that carries a lot of value. A credible buy for those with longer horizons.
  99. It's Time To Invest In Switzerland

    October 19, 2011
    Swiss stocks may offer a more conservative hiding place.
  100. Time To Invest In Switzerland?

    September 26, 2011
    Swiss stocks may offer a more conservative hiding place.
  101. Endo And Forest – Dumpster-Diving In Pharma

    September 21, 2011
    Endo and Forest have problems; however, the valuations seem excessively low.
  102. When Times Are Tough, Should Investors Go Swiss?

    September 15, 2011
    Swiss stocks may offer a more conservative hiding place.
  103. PerkinElmer Adds High-End Tools To Its Box

    September 13, 2011
    Caliper's rebound comes to an end with a premium take-out by PerkinElmer.
  104. Seattle Genetics – And Now The Hard Bit

    August 23, 2011
    Seattle Genetics got a much-needed FDA approval, but the sales ramp could be challenging for the stock.
  105. A Blue-Chip Bargain Hunter's Bonanza

    August 21, 2011
    Valuations for the large caps are reaching the most attractive levels in decades, writes Paul Larson of Morningstar StockInvestor. ...
  106. Why Insiders Are Buying This Biotech Stock

    August 15, 2011
    There are a number of fundamental developments that have spurred recent purchases of Celgene.
  107. 10 Drug Firms to Profit on Biosimilars

    July 28, 2011
    Over the next five years, the market for "biosimilars" is forecast to climb to $10 billion worldwide, as many brand-name ...
  108. Going Global

    July 25, 2011
    Most investors never stray away from their home nations when it comes to portfolio construction.
  109. 6 Big Dividends to Boost Your Portfolio

    July 24, 2011
    With the current high levels of market and economic uncertainty, Oliver Pursche believes it’s crucial to stabilize ...
  110. Vical Gets Some Validation

    July 19, 2011
    Vical gets a small victory with a partnership for its CMV drug.
  111. 10 Drug Stocks for Safety and Yields

    June 26, 2011
    Big pharma is an attractive destination for traders and investors looking for safety, yields, and solid value in the current ...
  112. Should Investors Worry If Gen-Probe Doesn't Sell Out?

    June 10, 2011
    Not selling may be the best move Gen-Probe can make for its shareholders.
  113. A Dull ASCO And The Usual Sell-Off

    June 7, 2011
    Investors shouldn't be spooked by the normal post-ASCO sell-off
  114. Will Nestle Succeed Where Others Have Failed?

    May 26, 2011
    Nestle is making an interesting step into medical pharmaceuticals and diagnostics.
  115. With Mylan, Maybe Smaller Is Better

    May 6, 2011
    Mylan is not the biggest or the best, but the valuation here makes it worth a look.
  116. Teva And Cephalon Solve Each Other's Problems

    May 4, 2011
    Teva's acquisition of Cephalon is a logical deal that solves problems for each company.
  117. J&J Beats Analyst Expections, But Not Its Rivals

    April 25, 2011
    Tangible signs of sustained sales growth and consistent profit expansion are still absent at J&J.
  118. Quest Diagnostics Opens Its Wallet One More Time

    March 22, 2011
    Quest shows once again that it is willing to pay for what may become valuable testing technology.
  119. Medicis - Generic Reprieve And Shareholder Relief

    March 2, 2011
    Medicis gets a big boost from patent settlements.
  120. Novavax Gets A Booster Shot From The Government

    March 1, 2011
    Novavax gets a sizable contract from the government that will largely fund its remaining clinical trials for flu vaccines.
  121. Tepid Teva Somewhat Tempting

    February 9, 2011
    Teva's results and outlook will likely leave the stock cooling its heels for a bit in this growth-obsessed market, but patient ...
  122. A Foursome Of Pharma Earnings Suggests Business Is Still Tough

    January 31, 2011
    There's little growth to excite pharma investors, but there is more value here than some realize.
  123. Risk With Little Reward At Johnson & Johnson

    January 27, 2011
    A number of Johnson & Johnson rivals trade at equally appealing valuations and have their acts together in terms of product ...
  124. Forest Labs Has Wood To Chop

    January 19, 2011
    Will Forest be able to plug a gaping hole in its future revenue?
  125. Opportunities Are Rising In Japan

    January 17, 2011
    Although many investors ignore developed markets in favor the faster growing emerging markets, Japan may represent a deep ...
  126. Prescribing Healthcare Stocks For Your Portfolio

    January 14, 2011
    Despite the recent bad year, healthcare stocks remain a great long term opportunity.
  127. A Look At The Drug Makers Of 2010

    December 30, 2010
    Drug makers faced an uphill fight in 2010 and next year is looking to be just as tough.
  128. Has Ingenico Done VeriFone A Favor?

    December 23, 2010
    By rebuffing Danaher, Ingencio may be helping VeriFone.
  129. Novartis Brings Alcon Into The Fold

    December 16, 2010
    Novartis closes the deal for Alcon.
  130. Cooper: A Growing Play On Eye Care

    December 10, 2010
    Cooper is continuting to grow very well in a tough healthcare market, and shows signs of a shining future.
  131. How To Hide In Europe

    November 18, 2010
    With focus now returning to the European debt crisis, the time maybe here for investors to skip the broad bets and hone in ...
  132. Can Investors Warm To Warner Chilcott?

    November 9, 2010
    WCRX has levered up its risk but could still be a value.
  133. The Best Health Care For Your Investment Dollar

    October 26, 2010
    The healthcare sector is looking like a strong area of the economy, and potentially a very lucrative investment.
  134. Should Investors Take A Chance On Savient?

    October 26, 2010
    Savient's inability to sell itself puts almost everything about the company's value in flux.
  135. Investing Ideas From The Appleseed Portfolio

    October 20, 2010
    The Appleseed Fund is the best socially responsible investment fund over a three-year period. We'll look at some of its holdings.
  136. Can Savient Soar On One Specialty Drug?

    September 16, 2010
    Obtaining FDA approval is only part of the story for this one-drug company.
  137. Top-Heavy Pharmaceuticals

    August 27, 2010
    Investors should keep an eye on how much drug companies rely on its top sellers.
  138. Biosimilars - The Next Generic Honeypot

    August 10, 2010
    With the first biosimilar approval in over a decade, a major new market for generics could be on the horizon
  139. Profit From Teva's Travails

    July 29, 2010
    Wall Street is giving investors the chance to purchase a top-tier generics company at a discount price.
  140. An Unsurprising Increase In Biotech Acquisitions

    July 28, 2010
    The Sanofi/Genzyme combination isn't the only biotech M&A activity on the radar.
  141. Bypass The Euro With Switzerland

    May 19, 2010
    As the crisis within the EU countries intensifies, investors may want to put Switzerland on their map.
  142. Drug Companies With Tasty Medicine

    May 7, 2010
    Merck is just one of the drug companies offering up tantalizing earnings per share.
  143. GlaxoSmithKline On Simmer

    April 30, 2010
    Glaxo's earnings look powerful, but is this really a top idea in the pharma sector?
  144. Pharmaceutical Profits That Aren't For The Dogs

    March 15, 2010
    Merck and Sanofi-Aventis recently combined their animal health businesses, lending further evidence to the notion that this ...
  145. There's Nothing Generic About the Profits

    January 27, 2010
    Any healthcare reform will include severe cost cutting. Giving your portfolio a dose of generic-dug makers will help you ...
  146. A Review Of The Drug Makers Of 2009

    December 29, 2009
    Corporate deal-making was the name of the big pharma game in 2009 and will likely continue into the new year.
  147. H1N1 Vaccines Finally Bearing Revenue

    December 9, 2009
    Investors lost interest in swine flu vaccine stocks, like AZN and GSK, before they had a chance to enjoy any revenue.
  148. Pay Attention To QLT

    October 29, 2009
    Learn how you effectively get the biopharmaceutical company for free.
  149. Long-Term Flu Plays

    October 2, 2009
    Flu vaccine shares still have long-term appeal.
  150. Swine Flu Vaccine: Quantity Over Quality

    July 20, 2009
    The swine flu vaccine race appears to have multiple winners.
  151. Raising the Roof: Dividend Payments Rising

    February 27, 2009
    Stocks that are increasing their payouts could be the ones to watch.
  152. Wyeth's Day In Court

    November 6, 2008
    Wythe and other drug companies are anxiously awaiting the outcome a product labeling liability case before the U.S. Supreme ...
  153. Aging Population Feeds Global Healthcare Demand

    October 30, 2008
    Investing in foreign-based healthcare providers is as important as investing in healthcare providers with a global reach.
  154. Alcon Takes A Poke In The Eye

    October 28, 2008
    Despite investor worries over Alcon's growth, the eye care company is a proven winner.
  155. Pfizer Drug Development Ahead Of Schedule

    October 6, 2008
    Pfizer's late-stage drug pipeline has gone from 16 to 25 drugs in six months, and a high dividend cushions returns while ...
  156. Sleep Easy With Abbott Labs

    October 3, 2008
    Security and stability reign at Abbott Labs. The drug maker has avoided major recalls and has rock solid patent protection.
  157. Let Johnson & Johnson Band-Aid Your Portfolio

    August 1, 2008
    Johnson & Johnson produced record Q2 sales overseas. Learn how its diverse product lineup provides a bear-proof revenue stream.
  158. Abbott Labs Finally Turns Potential Into Profit

    April 17, 2008
    Solid numbers for the last two quarters could change Abbott Labs's reputation as an overvalued stock.
  159. Green Funds For The Faint Of Heart

    March 24, 2008
    Learn about two funds that go green without going overboard. Both invest in well-known companies with strong growth potential.
  160. Leap Of Faith Healing (MEDX, PDLI, AMLN)

    August 8, 2007
    Make the leap with three pharmaceutical companies who require investor courage but could provide a healthy return.
  161. Bristol-Myers Hurt By Plavix, Saved By Demographics (BMY)

    November 16, 2006
    Despite BMY's recent struggles with its Plavix sales, favorable demographics make the stock a good investment to consider.
  162. Winners and Losers: July 24th - 28th (MNTA, NG, ALDA, CDI)

    July 28, 2006
    The market's big winners and losers for the week of July 24th to 28th.
  163. A Look at Economic Moats - Part 2

    November 23, 2005
    In this piece we'll explore different types of economic moats.
Investing News
  1. Outside the Box: Hoisington Investment Management Quarterly Review and Outlook, First ...

    Outside the Box: Hoisington Investment Management Quarterly Review and Outlook, First Quarter ...
  2. Why Stick With Energy Stocks? (Hint: Geopolitical Risk)

    By most fundamental measures, oil prices should be declining. Russ explains why they’re on ...
  3. Bad Investor Behavior: Overemphasizing Experience

    Behavioral finance researchers have discovered that our personal experiences disproportionately ...
  4. Thoughts From The Frontline: Every Central Bank For Itself

    Thoughts from the Frontline: Every Central Bank for Itself
  5. 3 Dumb Ways to Borrow Money

    Money — everyone needs it, but not everyone has it. Many people who find themselves in a ...
  6. Infographic - The Lifecycle of a Bond

    Basic information on how Bonds work.
Trading Center